How might cancer vaccines and cell therapy merge in the future?

Question

Accepted Answer

Cancer Vaccines and Cell Therapy Poised for Convergence

The landscape of cancer treatment is expected to witness a significant convergence between cancer vaccines and cell therapy over the next five years. This evolution is driven by advancements in delivering therapeutic payloads directly into a patient's cells, potentially streamlining current complex and costly treatment modalities. A key development involves in vivo reprogramming, where lipid nanoparticles (LNPs) carrying messenger RNA (mRNA) are used to introduce genetic material into a patient's T cells. This mRNA can encode not only antigens but also chimeric antigen receptors (CARs).
In Vivo Reprogramming with mRNA-LNPs

A central prediction is the blurring of lines between vaccines and cell therapy, largely due to the advent of in vivo reprogramming. This process utilises LNPs to deliver mRNA encoding specific therapeutic elements directly into a patient's T cells. The potential outcome is a single infusion that effectively transforms a patient's lymph nodes into manufacturing sites for CAR-T cells. This approach could circumvent the substantial costs and intensive toxic preconditioning regimens currently associated with traditional CAR-T therapies, which often involve significant chemotherapy.
Redefining "Vaccine" by 2028

By the year 2028, the term "vaccine" may encompass a more sophisticated multi-epitope mRNA-LNP formulation. Such a formulation would be designed to achieve two critical functions simultaneously: the expansion of neoantigen-specific T cells and the deployment of a bispecific T cell engager. The latter component is crucial for overcoming the immunosuppressive tumor microenvironment, a significant barrier to effective T cell-mediated cancer eradication. This integrated approach aims to enhance the immune system's ability to recognize and attack cancer cells more effectively.
Overcoming Tumor Microenvironment Challenges

Current challenges in cancer treatment often stem from the tumor microenvironment (TME), which can actively suppress or destroy immune cells. The proposed advancements aim to directly address this issue. By delivering mRNA encoding not only antigens but also CARs, the in vivo reprogramming strategy seeks to equip the patient's own T cells with the machinery to target cancer cells. Furthermore, the predicted 2028 "vaccine" would incorporate bispecific T cell engagers, designed to bridge T cells and tumor cells, thereby facilitating tumor cell killing and mitigating the immunosuppressive effects of the TME.

Reading history

Hide →

This history is cleared when the page is closed.

How might cancer vaccines and cell therapy merge in the future?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends